Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporti...

Descripción completa

Detalles Bibliográficos
Autores principales: Domachowske, Joseph B, Chang, Yue, Atanasova, Victoria, Cabañas, Fernando, Furuno, Kenji, Nguyen, Kim A, Banu, Irfana, Kubiak, Robert J, Leach, Amanda, Mankad, Vaishali S, Shroff, Manish, Takas, Therese, Villafana, Tonya, Wählby Hamrén, Ulrika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583/
https://www.ncbi.nlm.nih.gov/pubmed/37466917
http://dx.doi.org/10.1093/jpids/piad052
_version_ 1785099473746132992
author Domachowske, Joseph B
Chang, Yue
Atanasova, Victoria
Cabañas, Fernando
Furuno, Kenji
Nguyen, Kim A
Banu, Irfana
Kubiak, Robert J
Leach, Amanda
Mankad, Vaishali S
Shroff, Manish
Takas, Therese
Villafana, Tonya
Wählby Hamrén, Ulrika
author_facet Domachowske, Joseph B
Chang, Yue
Atanasova, Victoria
Cabañas, Fernando
Furuno, Kenji
Nguyen, Kim A
Banu, Irfana
Kubiak, Robert J
Leach, Amanda
Mankad, Vaishali S
Shroff, Manish
Takas, Therese
Villafana, Tonya
Wählby Hamrén, Ulrika
author_sort Domachowske, Joseph B
collection PubMed
description In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
format Online
Article
Text
id pubmed-10469583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104695832023-09-01 Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease Domachowske, Joseph B Chang, Yue Atanasova, Victoria Cabañas, Fernando Furuno, Kenji Nguyen, Kim A Banu, Irfana Kubiak, Robert J Leach, Amanda Mankad, Vaishali S Shroff, Manish Takas, Therese Villafana, Tonya Wählby Hamrén, Ulrika J Pediatric Infect Dis Soc Brief Report In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease. Oxford University Press 2023-07-19 /pmc/articles/PMC10469583/ /pubmed/37466917 http://dx.doi.org/10.1093/jpids/piad052 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Domachowske, Joseph B
Chang, Yue
Atanasova, Victoria
Cabañas, Fernando
Furuno, Kenji
Nguyen, Kim A
Banu, Irfana
Kubiak, Robert J
Leach, Amanda
Mankad, Vaishali S
Shroff, Manish
Takas, Therese
Villafana, Tonya
Wählby Hamrén, Ulrika
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title_full Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title_fullStr Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title_full_unstemmed Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title_short Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
title_sort safety of re-dosing nirsevimab prior to rsv season 2 in children with heart or lung disease
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583/
https://www.ncbi.nlm.nih.gov/pubmed/37466917
http://dx.doi.org/10.1093/jpids/piad052
work_keys_str_mv AT domachowskejosephb safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT changyue safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT atanasovavictoria safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT cabanasfernando safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT furunokenji safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT nguyenkima safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT banuirfana safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT kubiakrobertj safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT leachamanda safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT mankadvaishalis safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT shroffmanish safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT takastherese safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT villafanatonya safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease
AT wahlbyhamrenulrika safetyofredosingnirsevimabpriortorsvseason2inchildrenwithheartorlungdisease

Ejemplares similares